Vir Biotechnology (VIR) Gains from Investment Securities (2018 - 2026)
Vir Biotechnology recorded quarterly Gains from Investment Securities of $170000.0 in Q1 2026, down 98.54% quarter-over-quarter from $11.7 million in Q4 2025, and up 102.66% year-over-year from $83882.8 in Q1 2025.
Vir Biotechnology's Gains from Investment Securities history runs 9 years deep, the most recent figure standing at $170000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 102.66% year-over-year to $170000.0; the TTM figure through Mar 2026 stood at $13.9 million (up 305.07% YoY), while the FY2025 annual figure was $7.3 million, up 32.58% from the prior year.
- Gains from Investment Securities came in at $170000.0 for Q1 2026 at Vir Biotechnology, down from $11.7 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $119.9 million in Q3 2022 to a low of -$20.9 million in Q4 2023.
- A 5-year average of $7.8 million and a median of $122760.0 in 2022 frame the typical range for Gains from Investment Securities.
- On a YoY basis, Gains from Investment Securities climbed as much as 17250.37% in 2023 and fell as far as 21715.0% in 2023.
- Vir Biotechnology's Gains from Investment Securities stood at -$8.9 million in 2022, then tumbled by 135.33% to -$20.9 million in 2023, then surged by 126.46% to $5.5 million in 2024, then surged by 111.0% to $11.7 million in 2025, then plunged by 98.54% to $170000.0 in 2026.
- According to Business Quant data, Gains from Investment Securities over the past three periods registered $170000.0, $11.7 million, and -$11.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 170,000.00 |
| Mar 31, 2026 | 170,000.00 |
| Dec 31, 2025 | 11.66 Mn |
| Dec 31, 2025 | 11.66 Mn |
| Sep 30, 2025 | -11.93 Mn |
| Sep 30, 2025 | -11.93 Mn |
| Jun 30, 2025 | 13.97 Mn |
| Jun 30, 2025 | 13.97 Mn |
| Mar 31, 2025 | -6.38 Mn |
| Mar 31, 2025 | -6.38 Mn |
| Dec 31, 2024 | 5.53 Mn |
| Dec 31, 2024 | 5.53 Mn |
| Jun 30, 2024 | -5.92 Mn |
| Jun 30, 2024 | -5.92 Mn |
| Mar 31, 2024 | 5.92 Mn |
| Mar 31, 2024 | 5.92 Mn |
| Dec 31, 2023 | -20.90 Mn |
| Dec 31, 2023 | -20.90 Mn |
| Sep 30, 2023 | 20.76 Mn |
| Sep 30, 2023 | 20.76 Mn |
| Jun 30, 2023 | -12.97 Mn |
| Jun 30, 2023 | -12.97 Mn |
| Mar 31, 2023 | 13.10 Mn |
| Mar 31, 2023 | 13.10 Mn |
| Dec 31, 2022 | -8.88 Mn |
| Dec 31, 2022 | -8.88 Mn |
| Sep 30, 2022 | 119.90 Mn |
| Sep 30, 2022 | 119.90 Mn |
| Jun 30, 2022 | 60,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 75,520.00 |
| Mar 31, 2022 | 75,520.00 |
| Dec 31, 2021 | -187,000.00 |
| Dec 31, 2021 | -187,000.00 |
| Sep 30, 2021 | 3.01 Mn |
| Sep 30, 2021 | 3.01 Mn |
| Jun 30, 2021 | 628,801.00 |
| Jun 30, 2021 | 628,801.00 |
| Sep 30, 2020 | 514,889.00 |
| Sep 30, 2020 | 514,889.00 |
| Jun 30, 2020 | 280,876.00 |
| Jun 30, 2020 | 280,876.00 |
| Mar 31, 2020 | 923,104.00 |
| Mar 31, 2020 | 923,104.00 |
| Dec 31, 2019 | 4.93 Mn |
| Dec 31, 2019 | 4.93 Mn |
| Sep 30, 2019 | 2.33 Mn |
| Sep 30, 2019 | 2.33 Mn |
| Jun 30, 2019 | 427,000.00 |
| Jun 30, 2019 | 427,000.00 |
| Mar 31, 2019 | 357,000.00 |
| Mar 31, 2019 | 357,000.00 |
| Dec 31, 2018 | -2.05 Mn |
| Dec 31, 2018 | -2.05 Mn |